Compare Krispy Kreme Inc (DNUT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs Moderna, Inc. — how do they compare? Krispy Kreme Inc trades at $2.98 (market cap $521.37M), while Moderna, Inc. trades at $220.84 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 150.9× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 46 Days and Moderna, Inc. for 59 Days on average.
| DNUT | MRNA | |
|---|---|---|
Market Cap | $521.37M | $78.65B |
Volume | 2,293,015 | 37,373,437 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $203.46 |
52-Week Low | $2.87 | $22.36 |
Typical Hold Time | 46 Days | 59 Days |
Enterprise Value | $1.76B | $74.80B |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $2.945, up 0.86% with a bullish technical signal despite mixed earnings. The company shows strong gross margins (75.19%) but negative net income (-$515.77M for 2025) and declining revenue trends. Analyst sentiment is positive with 50% buy ratings, though recent news highlights ongoing legal investigations into fiduciary duties.
Investment outlook remains cautious due to profitability challenges and legal overhangs, offset by low valuation multiples (P/S 0.35) and product innovation. Key risks include sustained losses, debt burden, and litigation outcomes. Upside depends on margin improvement and successful new launches.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
